Issue link: https://www.e-digitaleditions.com/i/1138630
16 July 2019 Tablets & Capsules bility aren't considered during planning, the manufactur- ing plan might fall through with no backup or production scale might not meet demand. Understanding the options and their design and for- mulation ramifications from the beginning is critical and can save time and money and reduce frustration. The nature of the proposed product, the strength of market competition, and likely clinical strategies are all relevant. The right choices will result in a formulation that remains viable from its approval through to the end of the product's lifespan. Choice of tablet or capsule To ensure the success of an OCR product, consider the complexity of the performance requirements with respect to the patient, dissolution profiles, and clinical and manufacturing requirements. Also consider the price point needed to compete in the marketplace. For exam- ple, tablets may be the best option to limit manufacturing costs for simple products with stiff market competition. As an exercise to illustrate the types of decisions required, consider two product types: 1) monolithic hydrophilic matrix tablets and 2) two-piece, hard gelatin capsules containing one or more populations of Wurster- coated multiparticulate beads. Each of these common for- mats has pros and cons with respect to desired perfor- mance and from the very different perspectives of formulation, processing, and economics. Patients. Capsules are generally easier to swallow than tablets. Also, patients or caregivers can open the capsules and sprinkle the contents on food to aid in swallowing, and the API(s) will still release correctly. Tablets, espe- cially if not coated, are more likely to stick in the patient's throat and cause gastric irritation. Dissolution profiles. Because monolithic tablets have only a single matrix, a tablet that contains multiple APIs will release them simultaneously. Formulators cannot fine tune each API's dissolution profile or prevent the APIs from interacting without additional processing steps. In contrast, OCR multiparticulate capsules can contain separate populations of beads to keep multiple APIs sepa- rate and/or to have them release at different times, achiev- ing complex release patterns. Developing each of the vari- ous bead populations is costly and requires its own process step, however, increasing development time and cost, manufacturing cycle times, and testing requirements. Clinical development. Clinical development often calls for alterations in dose or release pattern. Furthermore, the product might require a range of dos- ages for titration or tapering. Unfortunately, after a tab- let's release profile is customized, any change in the for- mula may necessitate complete redevelopment. This may require re-evaluating polymer selection, tablet size, and API content. In contrast, because multiparticulate cap- sules package APIs as beads that behave independently, the dose or component release profile can be easily adjusted without affecting other product attributes. In addition to evaluating the advantages and disadvan- tages of each dosage form for the intended product, con- sider other critical product characteristics, including sta- bility, cost, ease of scale-up and tech transfer, required expertise, equipment capacity, cycle time, API interac- tions, dosing flexibility, and abuse potential. Development, scalability, and transfer Feasibility is a chief concern for pharmaceutical devel- opers considering OCR projects, and poor technology choices or planning can be disastrous. Manufacturing may be too expensive, time-consuming, or technically ineffective, and if scale-up, scale-down, and transfer feasi- Photo 2: OCR multiparticulate capsules can contain separate populations of beads to keep multiple APIs separate and/or to have them release at different times, achieving complex release patterns.

